Serina Therapeutics (SER) Investor presentation summary

Platform technology and innovation

• POZ platform enables improvements in small molecules, RNA, and ADCs, offering optimized targeting, reduced immunogenicity, and improved drug delivery.

• POZ (poly 2-oxazoline) addresses limitations of other polymers, allowing greater drug loading, controlled release, and safe metabolism.

• Enables continuous drug delivery via enzymatic release, extending administration intervals and optimizing safety/efficacy.

Lead asset and clinical development

• SER-252 (POZ-apomorphine) targets advanced Parkinson's disease, aiming for best-in-class continuous dopaminergic stimulation.

• Large unmet need with >$2.1B–$3.3B peak annual sales potential; modest clinical risk due to known active drug.

• Differentiated by 2x/week subcutaneous dosing using Enable Injections' enFuse device, avoiding continuous pumps and skin reactions.

• Phase 1b trial in advanced PD patients planned for 2H 2025, with interim data on safety and efficacy.

Market opportunity and competitive landscape

• Advanced PD affects 150,000 in the US and 210,000 in EU/UK, with about half inadequately controlled on oral therapies.

• Competing products require invasive, continuously worn infusion devices, limiting quality of life.

• Analysts project rapid growth in infusion treatments for Parkinson's, despite invasive profiles.